Key Points
- Suma Krishnan sold 25,000 Krystal Biotech shares at an average price of $359.32, generating approximately $8.98 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving her with 1.30 million shares.
- Krystal Biotech reported quarterly EPS of $1.79, exceeding the $1.70 consensus estimate, while revenue of $119.22 million fell slightly short of expectations.
- Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $365.40; institutional investors own approximately 86.29% of the company.
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company's stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Krystal Biotech Price Performance
Shares of KRYS opened at $358.24 on Friday. Krystal Biotech, Inc. has a 1 year low of $136.73 and a 1 year high of $382.54. The stock has a 50 day simple moving average of $349.81 and a two-hundred day simple moving average of $307.38. The firm has a market cap of $10.60 billion, a P/E ratio of 44.89 and a beta of 0.54.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.
Wall Street Analyst Weigh In
KRYS has been the topic of a number of analyst reports. Chardan Capital upgraded shares of Krystal Biotech to a "strong-buy" rating in a research report on Monday, August 3rd. TD Cowen upped their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a "buy" rating in a research report on Thursday, June 18th. HC Wainwright raised their price objective on Krystal Biotech from $310.00 to $361.00 and gave the company a "buy" rating in a research note on Tuesday, June 16th. Wall Street Zen cut Krystal Biotech from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $365.40.
View Our Latest Stock Report on Krystal Biotech
Institutional Investors Weigh In On Krystal Biotech
Several institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LP grew its holdings in Krystal Biotech by 767.4% in the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company's stock worth $11,357,000 after acquiring an additional 27,035 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Krystal Biotech by 3.9% during the second quarter. HighTower Advisors LLC now owns 2,129 shares of the company's stock valued at $791,000 after acquiring an additional 80 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Krystal Biotech during the second quarter worth about $3,865,000. California State Teachers Retirement System boosted its holdings in shares of Krystal Biotech by 33,527.2% during the second quarter. California State Teachers Retirement System now owns 8,805,606 shares of the company's stock worth $3,272,780,000 after purchasing an additional 8,779,420 shares during the period. Finally, denkapparat Operations GmbH bought a new stake in shares of Krystal Biotech in the second quarter worth about $226,000. Hedge funds and other institutional investors own 86.29% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
